Literature DB >> 28628234

Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Cancer Orthotopic Mouse Model.

Takashi Murakami1,2,3, Yukihiko Hiroshima1,2,3, Yong Zhang1, Ming Zhao1, Tasuku Kiyuna1,2, Ho Kyoung Hwang1,2, Kentaro Miyake1,2, Yuki Homma3, Ryutaro Mori3, Ryusei Matsuyama3, Takashi Chishima3, Yasushi Ichikawa3, Kuniya Tanaka3, Michael Bouvet2, Itaru Endo3, Robert M Hoffman1,2.   

Abstract

The present study determined the effect of the tumor-targeting strain Salmonella typhimurium A1-R (S. typhimurium A1-R) on CD8+ tumor-infiltrating lymphocytes (TILs) in a syngeneic pancreatic-cancer orthotopic mouse model. The effect of tumor-targeting S. typhimurium A1-R on CD8+ TILs was determined on the Pan02 murine pancreatic-adenocarcinoma implanted orthotopically in the pancreatic tail of C57BL/6 immunocompromised mice. Three weeks after orthotopic implantation, mice were randomized as follows G1: untreated control group (n = 8); and G2: S. typhimurium A1-R-treatment group (n = 8, 1 × 107 colony forming units [CFU]/body, iv, weekly, 3 weeks). On the 22nd day from initial treatment, all mice were sacrificed and tumors were harvested. The tumor-volume ratio was defined as ratio of tumor volume on the 22nd day relative to the 1st day. The tumor volume ratio was significantly lower in the S. typhimurium A1-R-treated group (G2) (3.0 ± 2.8) than the untreated control (G1) (39.9 ± 30.7, P < 0.01). Hematoxylin and easin (H&amp;E) staining on tumor sections was performed to evaluate tumor destruction which was classified according to the Evans grading system and found to be much greater in the S. typhimurium A1-R-treated mice (G2). Six mice in G1 had peritoneal dissemination, whereas no mice showed peritoneal dissemination in G2 (P < 0.01). Immunohistochemical staining with anti-mouse CD8+ antibody was performed in order to detect TILs determined by calculating the average number of CD8+ cells in three high power fields (200×) in the treated and untreated tumors. The TIL score was significantly higher in G2 (133.5 ± 32.2) than G1 (45.1 ± 19.4, P < 0.001). The present study demonstrates that S. typhimurium A1-R promotes CD8+ T cell infiltration and inhibition of tumor growth and metastasis. J. Cell. Biochem. 119: 634-639, 2018.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  C57BL/6 MICE; CD8+ T CELLS; METASTASIS; ORTHOTOPIC MOUSE MODEL; PANCREATIC CANCER; Salmonella typhimurium A1-R; TUMOR INFILTRATION

Mesh:

Year:  2017        PMID: 28628234     DOI: 10.1002/jcb.26224

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

1.  A global bibliometric and visualized analysis of bacteria-mediated cancer therapy.

Authors:  Jiawei Wang; Mohammed Maniruzzaman
Journal:  Drug Discov Today       Date:  2022-05-30       Impact factor: 8.369

2.  Salmonella typhimurium A1-R Exquisitely Targets and Arrests a Matrix-producing Triple-negative Breast Carcinoma in a PDOX Model.

Authors:  Kazuyuki Hamada; Yusuke Aoki; Jun Yamamoto; Chihiro Hozumi; Ming Zhao; Takuya Murata; Norihiko Sugisawa; Michael Bouvet; Takuya Tsunoda; Robert M Hoffman
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 3.  Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy.

Authors:  Ze Mi; Zhi-Chao Feng; Cheng Li; Xiao Yang; Meng-Tian Ma; Peng-Fei Rong
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

Review 4.  Efficacy of Tumor-Targeting Salmonella typhimurium A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models.

Authors:  Takashi Murakami; Yukihiko Hiroshima; Kentaro Miyake; Tasuku Kiyuna; Itaru Endo; Ming Zhao; Robert M Hoffman
Journal:  Cells       Date:  2019-06-16       Impact factor: 6.600

5.  Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment.

Authors:  Suneesh Kaimala; Ashraf Al-Sbiei; Otavio Cabral-Marques; Maria J Fernandez-Cabezudo; Basel K Al-Ramadi
Journal:  Front Oncol       Date:  2018-05-01       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.